Mineralocorticoid receptor antagonism reduces morbidity and mortality in patients with heart failure, but the safety of these drugs in patients receiving dialysis is unclear. This study evaluated whether hyperkalemia and/or hypotension limited the use of eplerenone, a selective mineralocorticoid receptor antagonist, in hemodialysis patients.

The objective of the PHASE study was to determine the tolerability of eplerenone in patients with end state renal disease (ESRD) requiring dialysis.

This was a randomized controlled trial of prevalent patients receiving hemodialysis at five Canadian centres.

Primary endpoint:

Permanent discontinuation of the drug because of hyperkalemia or hypotension.

Secondary endpoints:

  • Hyperkalemia
  • Hypotension
  • Cardiovascular events.
Study Type

Interventional - Drug

Study Design

Randomized, double-blind, placebo control

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2012 - 2014



Back To Top